Fondaparinux sodium, also known by its popular brand name Arixtra, is an anticoagulant medication which is structurally similar to low molecular weight heparins, with heparins being a class of anticoagulant drugs. It was originally marketed by the pharmaceutical products company GlaxoSmithKline under the aforementioned brand name of Arixtra in the United States, where it originally gained FDA approval. Currently, generic versions of fondaparinux sodium exist, having been developed by Alchemia and commercialised by Dr Reddy's Laboratories. This has allowed fondaparinux sodium manufacturers and fondaparinux sodium suppliers to list the product for sale and wholesale in a cost efficient manner. Allowing distributors to sell the product on the global marketplace at a variety of price points.
Method of action of fondaparinux sodium:
Fondaparinux is a synthetic pentasaccharide factor Xa inhibitor functioning through binding to antithrombin and accelerating its inhibition of factor Xa. By selectively binding to antithrombin, fondaparinux increases the neutralization of factor Xa by antithrombin. This neutralization of Xa interrupts the coagulation cascade and subsequently inhibits the formation and development of thrombin. This thus prevents coagulation in a specific manner, making fondaparinux sodium efficient for use in its designed therapies, such as the treatment of various thrombosis and myocardial events, among others.
Form and dosage of fondaparinux sodium:
As with all drugs, the final form is dependent on the specific manufacturers and suppliers, as well as the intended purpose. Typically fondaparinux sodium manufacturers and distributors produce it in forms including a solution for injection, solution for infusion for injection, concentration for solution, and vials. It is a prescription-only medication, as such, it can only be administered under the advice of a medical professional. Although the dose administered is patient and treatment specific, typical values begin at an initial 2.5 mg through subcutaneous injection or intravenous injection, up to 10 mg every 24 hours. These however are recommended values, thus can vary widely, particularly based on the route of administration and patient body weight.
Fondaparinux sodium on Pipelinepharma:
At the time of current writing, we could not find any fondaparinux sodium manufacturers or fondaparinux sodium suppliers in our online database list of global trusted B2B wholesale distributors. This list is constantly being updated with the most current and relevant information. Each company listed on our online platform has been verified, in a time consuming and cost intensive manner, according to strict quality control by the Pipelinepharma team. As such, it is likely that fondaparinux sodium manufacturers and fondaparinux sodium suppliers are awaiting approval and will be listed soon.
Price of fondaparinux sodium and how to buy:
Although fondaparinux sodium is not currently available to order through our online pharmaceutical products B2B platform, this is subject to change at any moment, contingent on the verification of trusted suppliers. When a listing is published by a seller it will appear with either a ‘Get offer’ button or an ‘Accept’ and ‘Negotiate’ button. ‘Accept’ and ‘Negotiate’ will only appear if the manufacturers have provided the desired cost for their product. This streamlines the transaction process, providing a baseline for negotiations and expectations.